Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.

About this update from Oncolytics Biotech Inc.

[{"type":"text","content":"\n\n\n\nOncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY and SAN DIEGO, June 29, 2017\n\n\n\nResponsible for Global Partnering and Business Development\n\n\n\nCALGARY and SAN DIEGO, June 29, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced the appointment of Andrew de Guttadauro as President of its US subsidiary, Oncolytics Biotech (U.S.) Inc.  Mr. de Guttadauro, based in the Company's recently opened satellite office in San Diego, California, will primarily be responsible for simultaneously pursuing both global and regional licensing, partnership and commercialization opportunities for REOLYSIN®.  \n\n\"Mr. de Guttadauro brings a breadth of industry knowledge, experience and relationships to the Company and we are excited that he has chosen to join us,\" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. \"Andrew will lead our business development efforts, focusing on advancing the development and eventual commercialization of REOLYSIN.  He represents an important expansion of our team as we seek to capitalize on our compelling survival data in late stage breast cancer patients and potentially to deliver new sources of non-dilutive investment in the Company.\"  \n\n\"I was excited to see a late stage immuno-oncology viral agent like REOLYSIN, with such strong efficacy and safety data, maintain its global rights,\" said Mr. de Guttadauro. \"I am looking forward to joining a mature and growing team as we advance partnership discussions and prepare for our phase three registration study in metastatic breast cancer.\"\n\nMr. de Guttadauro has more than 25 years of proven biopharmaceutical commercialization and business development experience. He was most recently a Principal at 1798 Consultants Inc., a healthcare strategic advisory firm providing commercialization consulting services across a number of areas inclu...

More updates from Oncolytics Biotech Inc.